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EPIDEMIOLOGY/POPULATION STUDIES
Impact of the 2003 to 2018 Population Salt 
Intake Reduction Program in England
A Modeling Study
Sergi Alonso , Monique Tan , Changqiong Wang, Seamus Kent, Linda Cobiac, Graham A. MacGregor, Feng J. He,  
Borislava Mihaylova
ABSTRACT: The United Kingdom was among the first countries to introduce a salt reduction program in 2003 to reduce 
cardiovascular disease (CVD) incidence risk. Despite its initial success, the program has stalled recently and is yet to achieve 
national and international targets. We used age- and sex-stratified salt intake of 19 to 64 years old participants in the 
National Diet and Nutrition Surveys 2000 to 2018 and a multistate life table model to assess the effects of the voluntary 
dietary salt reduction program on premature CVD, quality-adjusted survival, and health care and social care costs in England. 
The program reduced population-level salt intake from 9.38 grams/day per adult (SE, 0.16) in 2000 to 8.38 grams/day per 
adult (SE, 0.17) in 2018. Compared with a scenario of persistent 2000 levels, assuming that the population-level salt intake 
is maintained at 2018 values, by 2050, the program is projected to avoid 83 140 (95% CI, 73 710–84 520) premature 
ischemic heart disease (IHD) cases and 110 730 (95% CI, 98 390–112 260) premature strokes, generating 542 850 
(95% CI, 529 020–556 850) extra quality-adjusted life-years and £1640 million (95% CI, £1570–£1660) health care cost 
savings for the adult population of England. We also projected the gains of achieving the World Health Organization target 
of 5 grams/day per adult by 2030, which by 2050 would avert further 87 870 (95% CI, 82 050–88 470) premature IHD 
cases, 126 010 (95% CI, 118 600–126 460) premature strokes and achieve £1260 million (95% CI, £1180–£1260) extra 
health care savings compared with maintaining 2018 levels. Strengthening the salt reduction program to achieve further 
reductions in population salt intake and CVD burden should be a high priority. (Hypertension. 2021;77:1086-1094. DOI: 10.1161/
HYPERTENSIONAHA.120.16649.) • Data Supplement
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Excess salt intake is strongly linked with raised blood pressure (BP) and thereby increased risks of car-diovascular disease (CVD), as well as with kidney 
disease, gastric cancer, and osteoporosis,1–5 and is recog-
nized as a global health challenge.6 Raised BP (>115/75 
mm Hg) is responsible for half of the burden of ischemic 
heart disease (IHD) and >60% of stroke burden.7 Con-
sequently, the World Health Organization (WHO) and 
national governments have issued recommendations to 
reduce population-level salt intake.6,8 Different strategies 
have been implemented to achieve such reductions, most 
of them involving industry engagement toward voluntary 
salt reformulation in processed food.9 Partial success of 
such strategies has been observed in high-income coun-
tries, where about 80% of consumed salt comes from 
processed foods,10 including the United Kingdom where 
it represents up to 86% of all salt intake.11 Nevertheless, 
no country has yet achieved salt intake reductions to rec-
ommended levels.
Since 1996, the nongovernmental organization, 
Consensus Action on Salt and Health, have continu-
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reducing salt intake in the United Kingdom through 
providing scientific evidence and advocating political 
action.12 Such efforts contributed to a voluntary agree-
ment between the United Kingdom government and 
the food industry. In 2003 to 2010, the Food Standards 
Agency, in collaboration with the food industry, estab-
lished salt reduction targets in several food catego-
ries under a voluntary scheme,13 which also involved 
product labeling, public awareness campaigns, and 
monitoring of targets’ achievement. Reductions in the 
added salt in processed food were implemented gradu-
ally following a stepwise process.14 Consequently, the 
average population-level salt intake was reduced by 
15% in the period 2000 to 2011,15–17 with the decline 
attributed to food companies reformulating processed 
products rather than consumers switching to a lower 
salt diet.13 The program’s success was based on the 
fact that gradual marginal reductions are undetected 
by human taste receptors,18 thus, not affecting con-
sumers’ preferences or industry sales.
After several years of sustained salt intake reductions 
aimed at limiting the burden of excess salt by encour-
aging companies to reformulate recipes, in 2013, the 
National Institute for Health and Clinical Excellence rec-
ommended a maximum salt intake of 6 grams/day per 
adult by 2015 and 3 grams/day per adult by 2025.19 
From 2011 to 2017, the salt reduction program contin-
ued under the Department of Health as part of the Public 
Health Responsibility Deal. It first aimed to meet the 2012 
targets for reducing salt added into 85 food categories, 
such as bread, cheese, cereals, or soups; but it lacked 
the political commitment to achieve further reductions 
necessary to progress toward the recommended levels.15 
Few of the proposed actions were implemented under 
the Responsibility Deal and, thus, the program failed to 
achieve the salt intake targeted: in 2014, the average 
population-level salt intake among adults remained at 
about 8 grams/day.20 By 2018, however, an increase in 
salt intake was reported in adult women while no prog-
ress was reported in adult men.21
The present study evaluates the long-term effects of 
the 2003 to 2018 salt intake reduction program in Eng-
land using a model to project its effects on premature 
CVD, individuals’ healthy survival, and health care and 
social care costs. Moreover, it estimates the potential 
effects of further salt intake reductions by 2030.
METHODS
We evaluated the health and economic impact of reductions in 
population-level salt intake in England during the period 2003 to 
2018 by comparing population health outcomes and costs under 
the observed salt intake over the period 2003 to 2018 and 
assuming it remained at 2018 levels in 2019 to 2050 (base-
case analysis) with population-level salt intake maintained at 
2000 to 2001 values across the 2003 to 2050 period (compar-
ator; Figure 1). All data used in this study are publicly available.
Salt and Sodium
The terms salt and sodium are often used interchangeably. 
However, on a weight basis, salt comprises 40% sodium and 
60% chloride. Salt is the major source of sodium in the diet 
(≈90%). One gram of sodium=2.5 g of salt. Sodium is the term 
used in most scientific journals and in nutritional labels in the 
United States and Canada, and salt is used in Europe and other 
countries. We used the term salt throughout the article as it 
reports analysis for England.4
Nonstandard Abbreviations and Acronyms
CVD cardiovascular disease
IHD ischemic heart disease
BP blood pressure




• Between 2000 and 2018, the daily salt intake of 
adults in England declined by 1 gram/day, from 9.38 
to 8.38 grams/day.
What Is Relevant?
• We used 2000 to 2018 representative population sur-
veys’ salt intake data and a multistate life table model 
to project the impact of the 2000 to 2018 salt reduc-
tion program on cardiovascular disease, quality of life, 
health care and social costs and value of further salt 
reduction efforts in England.
Summary
We project that, if 2018 salt intake levels are main-
tained, by 2050, the 2000 to 2018 salt reductions 
would have led to 193 870 fewer adults developing 
premature cardiovascular disease; 542 850 more 
quality-adjusted life years; and large savings from 
reduced health care and social care utilization. If the 5 
grams/day, World Health Organization recommended 
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Population-Level Salt Intake Data
We used publicly available data on salt intake from the National 
Diet and Nutrition Surveys in adults 19 to 64 year of age in 
England21 that assessed salt intake by 24-hour urinary sodium 
excretion for a representative population sample in years 
2000/2001, 2006, 2008, 2011, 2014, and 2018. The data 
from complete urinary sodium samples (ie, para-amino benzoic 
acid ≥70%), stratified by sex and age (19–34, 35–49, ≥50) 
and adjusted using age- and sex-specific survey weights were 
used to estimate dietary salt intake (grams/day).
Salt Reduction Program Costs
The costs of the salt reduction program were based on esti-
mates by Collins et al,22 which were obtained from the Food 
Standards Agency Impact Assessment of 2009. Program 
activities under the Responsibility Deal were similar to 
those under the Food Standards Agency scheme, and, with 
the exception of the 2009 to 2012 media campaign, costs 
included: (1) food industry costs of reducing salt in specific 
food categories and (2) UK government costs of administer-
ing and monitoring the program. No extra food industry costs 
were considered as costs of labeling and reformulating spe-
cific product lines to reduce salt content were assumed to 
be fully absorbed during the natural product development life 
cycle22 and progressive salt reformulations were assumed not 
to impact on industry sales as consumers progressively adjust 
to lower-salt diets.17
UK government costs included the cost of a media cam-
paign conducted between 2009 and 2012 (£41.62 million), 
as well as the cost of monitoring salt intake in the general 
population and monitoring food industry activities to guarantee 
manufacturers are labeling and effectively reducing the salt 
content of food products (£2.15 million per year each).22 
Annual monitoring costs were assumed over the lifespan of 
the program, but future media campaigns were discontinued 
because of their limited effectiveness: public awareness of 
the salt-related harmful effects temporarily increased dur-
ing the campaigns but diminished quickly again after the first 
campaign year.14 We present program costs for the total pop-
ulation of England.
The PRIMEtime-CE Model: Impact on Health 
and Health Care Utilization
PRIMEtime-CE is a multistate life table model, which links 
sociodemographic and behavioral risk factors to noncommu-
nicable diseases’ morbidity and mortality and health and social 
care costs.23–29 Figure 2 summarizes the conceptual framework 
in our study.
We used official statistics on age and sex stratified popula-
tion distribution and all-cause mortality in England in the year 
2000.30,31 In mid-2000, the population of England was 49.2 
million, 51% of which were female, and 62% were aged above 
30 years (Figure S1 in the Data Supplement). All-cause mor-
tality rates were calculated using deaths registered by age and 
sex divided by corresponding population estimates (Figure S2). 
Population was annually adjusted in subsequent years using 
the age- and sex-specific rates of population increase during 
2000 to 2015. We used an open cohort design to account for 
all adults over time.
The effects of a reduction in population-level salt intake are 
propagated in the model through the reduction in BP.32 The 
effect of salt intake on BP is based on a meta-analysis by He et 
Figure 1. Population salt intake (grams/day) scenarios.
In the base-case analysis, we assessed the long-term health and economic impact of the achieved salt intake reduction during the period 
2003 to 2018, with 2018 levels maintained until 2050 (base-case scenario) compared with the population-level salt intake in 2000 
maintained until 2050 (area in green). In 2 further scenarios, the additional long-term impacts were assessed with further annual salt intake 
reductions in 2019 to 2030 of (scenario A) 1.37% (the annual reduction rate in 2000–2014); and (Scenario B) 3.36% (achieving the World 
Health Organization [WHO] recommendation of 5 grams/d per adult in 2030). In both scenarios, we assumed that 2030 salt-intake levels 
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al,32 which estimated that a reduction in salt intake of 6 grams/
day was associated with a decrease of 5.8 mm Hg (95% CI, 
2.50–9.20) in systolic BP. Salt intake changes in the model are 
implemented by sex and age and account for the positive asso-
ciation between higher dietary salt intake and BP: for a given 
reduction in salt intake, the fall in systolic BP is larger in older 
compared with younger individuals.33 Reductions in systolic BP 
are associated with reductions in risk of CVD, including IHD 
and stroke.34 During each year in the model, IHD and stroke 
prevalence and incidence were computed using population 
impact fractions, which accounted for the proportion by which 
disease incidence and mortality in the population were reduced 
given changes in BP because of the salt reduction program. 
Table S1 summarizes the parameters, probability distributions, 
and respective data sources used in the model; as well as the 
data sources informing the epidemiological estimates used in 
PRIMEtime-CE.
Quality-adjusted life-years (QALYs) were obtained by com-
bining life years and EQ-5D utilities, associated with included 
diseases,35 stratified by age and sex. During each year, the 
extra years and QALYs, and health care and social care cost 
savings due to reductions in IHD and strokes associated with 
the salt reductions achieved, were estimated (Methods in the 
Data Supplement).
Base-Case Analysis
We estimated the effects of the salt reduction program for 
the adult population in England, aggregated in 5-year bands, 
over the periods 2000 to 2018 and 2019 to 2050. For both 
study periods, age- and sex-specific CVD morbidity and mortal-
ity were simulated annually according to the risk associated 
with salt intake. Starting at 2000 levels, population salt intake 
was assumed to change according to the population-level salt 
intake observed in England from 2000 to 2018 and to remain 
at 2018 values for the remaining time horizon. Due to lack of 
data, individuals older than 64 years of age were assumed to 
have daily salt intake corresponding to the 50- to 64-year-old 
age and sex category. We estimated the total premature CVD 
morbidity and mortality cases, life-years, and QALYs, and health 
care and social care costs associated with 2000 to 2018 
salt intake values, and compared them with those obtained 
Figure 2. Conceptual framework.
PRIMEtime-CE is a multistate life table model for estimating the health and economic impact of health interventions.23–29 CVD indicates 
cardiovascular disease; NDNS, National diet and nutrition survey; ONS, office for national statistics; QALY, quality-adjusted life-year; and 
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should the salt intake levels remained at 2000 levels (base-
line; Figure 1). Health gains associated with the salt reduction 
program were expressed as: premature (ie, before 75 years of 
age) IHD and stroke cases avoided, and life years and QALYs 
gained. We considered IHD and stroke cases occurring to indi-
viduals dependent on BP reductions and adjusted for decreas-
ing trends in prevalence of CVD according to age and sex.36 
We present nondiscounted CVD cases, life years and QALYs, as 
well as discounted at 1.5% per annum QALYs gained with the 
salt reduction program.37
Health care and social care costs were presented in 2014 
UK£ values and discounted at an annual rate of 1.5%.37 Health 
care savings were calculated for the period 2000 to 2050 
as the difference between the cumulative health care costs 
associated with the salt intake levels before the salt reduction 
program (year 2000) minus the cumulative health care costs 
under decreasing population salt intake in 2000 to 2018. For 
the base-case analysis, we further calculated the incremental 
costs to the UK government as the government costs associ-
ated with monitoring and administering the salt reduction pro-
gram minus the cost savings due to reducing health care and/
or social care utilization.
Scenarios of Further Salt Reductions
We used PRIMEtime-CE to evaluate 2 additional scenarios 
with further population-level salt intake reductions after 2018. 
Between 2019 and 2030, we assumed a linear reduction in 
the average population-level salt intake (1) equivalent to the 
annual reduction rate of 1.37% observed over the period 2000 
to 2014 (scenario A) or (2) of 3.36% to achieve WHO recom-
mendation of 5 grams/day per adult (scenario B; Figure 1). We 
assumed that thereafter, salt intake was maintained at 2030 
levels until 2050. For each scenario, we estimated the health 
outcomes and health care and social care costs associated 
with reduced salt intake and expressed the outcomes as the 
additional premature morbidity and mortality cases averted, life-
years gained, QALYs gained, as well as the additional health 
care and social care savings compared with the base-case 
analysis (maintained salt intake at 2018 levels).
Sensitivity Analyses
We undertook a probabilistic sensitivity analysis to account for 
the uncertainty in model parameters using 1000 random draws 
from their probability distributions (Table S1) to estimate the 
SEs and 95% CIs.
Sensitivity analyses evaluated the impact of model parame-
ters on key results. First, we projected the long-term benefits if 
the program had not stalled in 2014 to 2018 by assuming con-
tinued decrease in salt intake from 2014 to 2030 at the 2000 
to 2014 annual rate with achieved reduction by 2030 main-
tained until 2050. Second, we evaluated the effect of assum-
ing the government salt reduction program was responsible for 
only half of the observed 2000 to 2018 salt intake decrease. 
Third, we assessed the impact of using a higher effect of a 
decrease in salt intake on BP, as estimated from observational 
data under a more prolonged period of lower salt intake (com-
pared with randomized trials), in which a decrease in salt intake 
of 1.4 grams/day, as measured by 24-hour urine sodium excre-
tion in a random population sample, was associated with a fall 
in systolic BP of 2.7 mm Hg.1 Finally, we used a higher sug-
gested estimate for 2014 population-level salt intake.38
RESULTS
Reduction in Population-Level Salt Intake and 
Its Short and Long-Term Effects
In 2000 to 2001, the average population-level salt 
intake was 9.38 grams/day (SE, 0.16), 10.72 grams/
day (SE, 0.25) in men, and 8.08 grams/day (SE, 0.18) 
in women. By 2014, the average population-level salt 
intake fell to 7.58 grams/day (SE, 0.18), 8.68 grams/
day (SE, 0.27) in men, and 6.43 grams/day (SE, 0.22) 
in women. The 19.20% reduction in salt intake in the 
period 2000 to 2001 to 2014 (Table S2) was some-
what larger in younger adults with >25% reduction in 
individuals 35 years of age or younger. However, the 
salt intake trend then stalled and by 2018, men had 
increased their intake to 9.19 grams/day (0.29) and 
women to 7.58 grams/day (0.23).
Table 1 reports the estimated impact of the achieved 
reduction in population-level salt intake on CVD burden 
and health care and social care cost. The model esti-
mated that 27 630 (95% CI, 26 580–27 650) premature 
IHD and 39 250 (95% CI, 38 500–40 050) premature 
stroke cases were avoided during the period 2000 to 
2018. These health gains translated into 33 660 (95% 
CI, 31 840–33 750) QALYs gained for the adult popula-
tion in England. In that period, the overall costs of the 
salt reduction program reached £103 million (95% 
CI, £103–£104), whereas the reduced CVD morbidity 
resulted in health care savings of £310 million (95% CI, 
£295–£311). Overall, the salt reduction program was 
cost-saving, estimated to save £860 million (95% CI, 
£830–£870) in health care and social care costs.
The model estimated that by 2050, even in the absence 
of further salt intake reductions (Table 1), 83 140 (95% 
CI, 73 710–84 520) premature IHD and 110 730 (95% 
CI, 98 390–112 260) premature stroke cases would be 
averted by achieved reductions to date, if maintained, 
compared with 2000 levels. Adopting a 50-year time 
horizon, the estimated UK government costs for the 
salt intake reduction program rose to 190 million (95% 
CI, £189–£191), whereas the estimated cost savings 
due to reducing health care and social care utilization 
increased to £7110 million (95% CI, £6940–£7230), 
and quality of life in England increased by 542 850 
(95% CI, 529 020–556 850) QALYs, or 334 660 (95% 
CI, 319 650–343 680) discounted QALYs (Table 1).
Further Salt Intake Reductions
The extra benefits with further salt intake reductions 
in the population of England on CVD morbidity and the 
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Reducing the population-level salt intake during 2018 to 
2030 at the same annual rate observed in 2000 to 2014 
was estimated to achieve average salt intake levels of 
6.77 grams/day per adult by 2030. Such a reduction 
was estimated to result in 37 870 (95% CI, 36 310–
38 550) further premature IHD cases and 56 310 (95% 
CI, 54 480–57 890) further premature stroke cases 
avoided by 2050, representing a 45% and 50% increase 
respectively of base-case results. Such health gains had 
additional health care and social care savings of £2560 
million (95% CI, £2510–£2620). Achieving larger popu-
lation salt intake reductions, as recommended by WHO, 
by 2030 implied an average salt intake reduction of 
3.38 grams/day per adult, which led to 87 870 (95% 
CI, 82 050–88 470) fewer premature IHD cases and 
126 010 (95% CI, 118 600–126 460) fewer premature 
stroke cases by 2050 compared with the health gains 
in the base-case analysis. This reduction in disease bur-
den led to 343 260 (95% CI, 334 810–352 430) further 
QALYs gained and additional cost savings of £5330 mil-
lion (95% CI, £5120–£5380). The program remained a 
cost-saving policy strategy.
Sensitivity Analyses
We investigated the impact of specific model assump-
tions on results. First, we estimated the impact if the salt 
intake reduction trend from 2000 to 2014 had continued 
until 2030 (Table S3). Under this scenario, the estimated 
premature CVD cases avoided doubled by 2050, with an 
additional 91 000 premature IHD cases and 143 700 pre-
mature stroke cases avoided, while the population quality 
of life in England increased by further 463 300 QALYs, 
compared with the base-case analysis. While health gains 
and governmental savings decreased when we attributed 
only 50% of salt intake reductions to the salt reduction 
program (Table S4), even under this assumption, the pro-
gram averted 29 300 premature IHD cases and 38 400 
premature stroke cases over 2000 to 2050, with £2500 
million government cost savings. Conversely, assuming a 
higher effect of salt intake reduction on BP doubled the 
premature CVD cases averted (Table S5) with 154 100 
premature IHD cases and 205 500 premature stroke 
cases averted in the period 2000 to 2050 (base-case); 
and further 312 400 premature IHD cases and 431 200 
premature stroke cases potentially averted if the WHO 
salt intake recommendation was achieved. Finally, adopt-
ing the adjusted 2014 salt intake estimates resulted in 
about 10% less health gains compared with the base-
case with the program remaining cost-saving (Table S6).
DISCUSSION
The 2003 to 2018 population salt reduction program 
put in place in England has been remarkably successful 
in reducing population-level salt intake. We report that, 
according to our model, this reduction projects 193 870 
fewer premature CVD cases and 542 850 extra QALYs 
Table 1. Projected Health Benefits and Costs of the 2003 to 2018 Salt Reduction Program Among Adults in 
England
Study outcome 2000–2018 2019–2050 Whole 2000–2050 period
Health benefits (95% CI)
 Premature IHD cases averted* 27 630 (26 580–27 650) 55 850 (54 080–57 610) 83 140 (73 710–84 520)
 Premature stroke cases averted* 39 250 (38 500–40 050) 72 110 (69 350–73 670) 110 730 (98 390–112 260)
 Years of life gained 37 130 (34 250–38 240) 702 960 (694 250–720 660) 740 090 (728 490–760 900)
 QALYs gained 33 660 (31 840–33 750) 516 190 (497 180–523 100) 542 850 (529 020–556 850)
 QALYs gained (discounted)† 27 490 (26 450–27 840) 307 170 (293 200–315 840) 334 660 (319 650–343 680)
Costs† (£ mln) (95% CI)
 Total care cost savings 960 (930–970) 6340 (6200–6450) 7300 (7130–7430)
 Health care cost savings 410 (400–420) 1220 (1170–1240) 1640 (1570–1660)
 Social care cost savings 550 (530–560) 5120 (5030–5210) 5670 (5560–5770)
  Government cost for salt reduction 
program
103 (103–104) 87 (86–87) 190 (189–191)
UK government cost savings‡ (£ mln) (95% CI)
 Total cost savings 860 (830–870) 6250 (6110–6370) 7110 (6940–7230)
  Cost savings excluding social care 
costs
310 (295–311) 1130 (1080–1160) 1450 (1380–1470)
Health effects and costs were estimated using the population-level salt intake reduction achieved during 2000 to 2018 and assuming the 
2018 levels were maintained until 2050 compared with a scenario with the 2000 salt intake levels were maintained until 2050. Costs expressed 
in 2014 UK£. CVD indicates cardiovascular disease; IHD, ischemic heart disease; mln, million; and QALY, quality-adjusted life-year.
*Premature cases are cases among adults up to 75 y of age.
†Discounted at 1.5% per annum.
‡Government cost savings calculated as the difference between the total health care and social care savings because of averted CVD minus 
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among the adult population in England by 2050. More 
importantly, further strengthening and scaling up of the 
salt reduction program, to achieve the WHO recommen-
dation of 5 grams/day per adult by 2030, could bring 
further large reductions in CVD burden with 213 880 
further premature CVD cases avoided by 2050. These 
health gains could bring substantial accumulated sav-
ings to the UK government of £5330 million by 2050 
due to reductions in population need for health care and 
social care.
Our results underscore the value of investing in public 
health interventions to reduce the burden of noncom-
municable diseases, with substantial savings to the UK 
government.39 The food industry in the UK is still produc-
ing high-salt products in spite of strong evidence that 
it is technologically feasible and commercially viable to 
produce lower-salt products, and there is ample room for 
incremental reductions in their salt content to achieve fur-
ther population salt reductions in the United Kingdom.15
The salt reduction program in England was highly suc-
cessful until 2011 because of the government pressure 
on industry to reduce salt content, resulting in a decline 
in the average population-level salt intake of 14% (Table 
S2; 8.3% reduction 2006–2011). A recent study reported 
5.1% reduction in the salt content of the UK grocery 
basket of a nationally representative sample of house-
holds from 2005 to 2011.13 These estimated reductions 
are consistent with the reduction reported by He et al, in 
high-salt products in supermarkets (from 3.3 to 1.8 g of 
salt per serving of product), which identified bread as the 
single largest contribution to salt to the UK diet: 18% of 
total salt intake.14 The salt reductions were also driven 
mainly by product reformulation, as opposed to net prod-
uct introduction and changes in consumer preferences.14 
The observed decline in program effectiveness after 
201121 was attributed to reduction in the government 
pressure on industry.15 To get back on track, the program 
will benefit from (1) a strict enforcement of salt reduction 
targets, for example, through legislation or financial pen-
alties for food companies failing to comply; (2) setting 
more stringent salt targets; and (3) extending salt targets 
to the out-of-home sector, which remain lenient and lack 
the proper monitoring mechanisms.
Several studies have previously indicated that salt 
reduction strategies have been effective and cost-effec-
tive in the United Kingdom,22,40–42 and worldwide.43–53 Our 
study adds further important evidence to the literature as 
it also includes the latest 2018 data on sodium excretion 
obtained from 24-hour urinary samples, that is, the most 
accurate way to assess salt intake, to estimate the health 
gains associated with reducing salt intake. Furthermore, 
we also project the reduction in CVD burden with further 
strengthening of salt reduction strategies to achieve the 
WHO recommendations on salt intake.
Despite the high-quality data on population-level salt 
intake and disease burden used, our study has some lim-
itations. First, the sample size for 24-hour urine collec-
tions was small, particularly after stratifying by age and 
sex. Second, our model does not capture the effect of 
salt intake on the burden of gastric cancer, renal disease, 
and osteoporosis,2,5,12 and, therefore, likely underesti-
mates the health benefits of the program. Moreover, the 
effect of salt reduction policies in children54 were also not 
included because of lack of salt intake data in children. 
Finally, the long study period may present a further limita-
tion due to the uncertainty in model parameters, assump-
tions on continuity of the salt reduction program, and 
evolution of CVD and salt intake trends. In particular, salt 
intake trajectories from 2019 onward are a main source 
of uncertainty, especially given the salt intake increase 
Table 2. Projected Benefits for Adults in England With Further Population Salt Intake Reductions Post-2018
Study outcome
Scenario A: 1.37% annual reduction in salt 
intake 2019–2030 (reaching 6.77 grams/d 
in 2030) and maintaining 2030 level to 2050
Scenario B: 3.36% annual reduction 
2019–2030 (reaching 5 grams/d in 2030) 
and maintaining 2030 level to 2050
Additional health benefits (95% CI)
 Additional premature IHD cases averted* 37 870 (36 310–38 550) 87 870 (82 050–88 470)
 Additional premature stroke cases averted* 56 310 (54 480–57 890) 126 010 (118 600–126 460)
 Additional years of life gained 220 530 (188 370–226 130) 451 930 (435 300–494 900)
 Additional QALYs gained 171 520 (167 340–220 530) 343 260 (334 810–352 430)
 Additional QALYs gained (discounted)† 95 120 (92 870–98 210) 189 540 (189 160–191 530)
Additional costs† (£ mln) (95% CI)
 Additional total care cost savings 2560 (2510–2620) 5330 (5120–5380)
 Additional health care savings 570 (540–580) 1260 (1180–1260)
 Additional social care savings 1980 (1970–2050) 4080 (3940–4120)
Effects of scenarios A and B were compared with maintaining 2018 levels until 2050. No additional government costs were included as costs of 
reformulating specific products were assumed to be absorbed by the food industry. Costs expressed in 2014 UK£. IHD indicates ischemic heart disease; 
mln, million; and QALY, quality-adjusted life-year.
*Premature cases are cases occurring up to 75 y of age.
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observed after 2014. However, the main objective of the 
current study was to highlight the long-term population 
health benefits should the government strengthen and 
enhance the UK salt reduction program.
PERSPECTIVES
The 2003 to 2018 salt reduction program in England 
achieved an overall salt intake reduction of 1 gram/day 
in the adult population from 9.38 grams/day per adult 
in 2000 to 8.38 grams/day per adult in 2018. We mod-
eled the long-term effects of this reduction and demon-
strated that the program led to reduced cardiovascular 
burden and improved quality-adjusted life expectancy of 
the adult population, as well as yielding large savings in 
health care and social care. However, reductions in salt 
intake achieved by 2014 are already being lost. Revers-
ing this and achieving the WHO recommended salt intake 
of 5 grams/day per adult requires continuous efforts in 
strengthening the implementation and monitoring of the 
program. Such efforts are shown likely to be well com-
pensated by further reductions in cardiovascular disease 
burden.
ARTICLE INFORMATION
Received November 5, 2020; accepted January 18, 2021.
Affiliations
From the Institute of Population Health Sciences (S.A., B.M.) and Wolfson Institute 
of Preventive Medicine (M.T., C.W., G.A.M., F.J.H.), Barts and The London School 
of Medicine and Dentistry, Queen Mary University of London, United Kingdom; 
National Institute for Health and Clinical Excellence, London, United Kingdom 
(S.K.); and Nuffield Department of Population Health, University of Oxford, United 
Kingdom (L.C., B.M.).
Sources of Funding
There were no external sources of funding for this study.
Disclosures
F.J. He is a member of the Consensus Action on Salt & Health group, a nonprofit 
charitable organization, and its international branch, World Action on Salt & Health, 
and does not receive any financial support from the Consensus Action on Salt 
& Health or World Action on Salt & Health. G.A. MacGregor is the Chairman of 
Blood Pressure UK, Chairman of the Consensus Action on Salt & Health, and 
Chairman of World Action on Salt & Health, and does not receive any financial 
support from any of these organizations. Blood Pressure UK, the Consensus Ac-
tion on Salt & Health, and World Action on Salt & Health are nonprofit charitable 
organizations. M. Tan and C. Wang are funded by the National Institute for Health 
Research (NIHR) (NIHR Global Health Research Unit Action on Salt China at 
Queen Mary University of London) using Official Development Assistance (ODA) 
funding (16/136/77). F.J. He and G.A. MacGregor are partially funded by the 
NIHR grant. The views expressed in this publication are those of the author(s) and 
not necessarily those of the NIHR or the Department of Health and Social Care.
REFERENCES
 1. He FJ, Pombo-Rodrigues S, MacGregor GA. Salt reduction in Eng-
land from 2003 to 2011: its relationship to blood pressure, stroke 
and ischaemic heart disease mortality. BMJ Open. 2014;4:e004549. 
doi:10.1136/bmjopen-2013-004549
 2. D’Elia L, Rossi G, Ippolito R, Cappuccio FP, Strazzullo P. Habitual salt intake 
and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr. 
2012;31:489–498. doi: 10.1016/j.clnu.2012.01.003
 3. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, 
Appel LJ, Whelton PK. Long term effects of dietary sodium reduction on car-
diovascular disease outcomes: observational follow-up of the trials of hyper-
tension prevention (TOHP). BMJ. 2007;334:885–888. doi: 10.1136/bmj. 
39147.604896.55
 4. He FJ, Tan M, Ma Y, MacGregor GA. Salt reduction to prevent hypertension 
and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 
2020;75:632–647. doi: 10.1016/j.jacc.2019.11.055
 5. Woo J, Kwok T, Leung J, Tang N. Dietary intake, blood pressure and osteo-
porosis. J Hum Hypertens. 2009;23:451–455. doi: 10.1038/jhh.2008.156
 6. World Health Organisation. Guideline: Sodium Intake for Adults and Children. 
Geneva; 2012.
 7. Lawes CMM, Hoorn SV, Law MR, Elliot P, MacMahon S, Rodgers A. Blood 
Pressure. Ezzati M, Lopez AD, Rodgers A, Murray CJL. Comparative Quan-
tification of Health Risks: Global and Regional Burden of Disease Attributable 
to Selected Major Risk Factors. Geneva, Switzerland; 2004.
 8. European Commission. The European Commission’s Science and Knowl-
edge Service. Dietary Salt/ Sodium. Brussels; 2019. https://ec.europa.eu/
jrc/en/health-knowledge-gateway/promotion-prevention/nutrition/salt. 
Accessed March 20, 2020
 9. Trieu K, Neal B, Hawkes C, Dunford E, Campbell N, Rodriguez-Fernandez R, 
Legetic B, McLaren L, Barberio A, Webster J. Salt reduction initiatives around 
the world - a systematic review of progress towards the global target. PLoS 
One. 2015;10:e0130247. doi: 10.1371/journal.pone.0130247
 10. James WP, Ralph A, Sanchez-Castillo CP. The dominance of salt in 
manufactured food in the sodium intake of affluent societies. Lancet. 
1987;1:426–429. doi: 10.1016/s0140-6736(87)90127-9
 11. Scientific Advisory Committee on Nutrition. Public Health England. Salt 
and Health. London, UK; 2003. https://assets.publishing.service.gov.uk/
government/uploads/system/uploads/attachment_data/file/338782/
SACN_Salt_and_Health_report.pdf.
 12. He FJ, Jenner KH, Macgregor GA. WASH-world action on salt and health. 
Kidney Int. 2010;78:745–753. doi: 10.1038/ki.2010.280
 13. Griffith R, O’Connell M, Smith K. The importance of product reformulation 
versus consumer choice in improving diet quality. Economica. 2017;84:34–
53. doi:10.1111/ecca.12192
 14. He FJ, Brinsden HC, MacGregor GA. Salt reduction in the United Kingdom: 
a successful experiment in public health. J Hum Hypertens. 2014;28:345–
352. doi: 10.1038/jhh.2013.105
 15. MacGregor GA, He FJ, Pombo-Rodrigues S. Food and the responsibility 
deal: how the salt reduction strategy was derailed. BMJ. 2015;350:h1936. 
doi: 10.1136/bmj.h1936
 16. Department of Health. Assessment of Dietary Sodium Levels among Adults 
(Aged 19-64) in England, 2011. London, UK; 2011. https://www.gov.uk/
government/publications/assessment-of-dietary-sodium-levels-among-
adults-aged-19-64-in-england-2011. Accessed July 15, 2019
 17. Wyness LA, Butriss JL, Stanner SA. Reducing the population’s sodium 
intake: the UK Food Standards Agency’s salt reduction programme. Public 
Health Nutr. 2012;15:254–261. doi: 10.1017/S1368980011000966
 18. Girgis S, Neal B, Prescott J, Prendergast J, Dumbrell S, Turner C, 
Woodward M. A one-quarter reduction in the salt content of bread can be 
made without detection. Eur J Clin Nutr. 2003;57:616–620. doi: 10.1038/sj. 
ejcn.1601583
 19. National Institute for Health and Care Excellence. Cardiovascular Disease 
Prevention. Manchester; 2010. https://www.nice.org.uk/guidance/ph25/
resources/cardiovascular-disease-prevention-pdf-1996238687173. 
Accessed July 15, 2019
 20. Government UK. PHE data on salt consumption levels. Public Health Eng-
land press office. Available at: https://www.gov.uk/government/news/new-
phe-data-on-salt-consumption-levels. Published 2016. Accessed July 15, 
2019
 21. Public Health England. National Diet and Nutrition Survey: Assessment of 
Salt Intake from Urinary Sodium in Adults (Aged 19 to 64 Years) in England, 
2018 to 2019. London, UK; 2020. https://www.gov.uk/government/sta-
tistics/national-diet-and-nutrition-survey-assessment-of-salt-intake-from-
urinary-sodium-in-adults-aged-19-to-64-years-in-england-2018-to-2019. 
Accessed March 30, 2020
 22. Collins M, Mason H, O’Flaherty M, Guzman-Castillo M, Critchley J, 
Capewell S. An economic evaluation of salt reduction policies to reduce 
coronary heart disease in England: a policy modeling study. Value Health. 
2014;17:517–524. doi: 10.1016/j.jval.2014.03.1722
 23. Briggs ADM, Cobiac LJ, Wolstenholme J, Scarborough P. PRIMEtime 

















Alonso et al Impact of the Salt Reduction Program in England
1094  April 2021 Hypertension. 2021;77:1086–1094. DOI: 10.1161/HYPERTENSIONAHA.120.16649
interventions affecting diet and physical activity. BMC Health Serv Res. 
2019;19:485. doi:10.1186/s12913-019-4237-4
 24. Scarborough P, Harrington RA, Mizdrak A, Zhou LM, Doherty A. The pre-
ventable risk integrated model and its use to estimate the health impact of 
public health policy scenarios. Scientifica (Cairo). 2014;2014:748750. doi: 
10.1155/2014/748750
 25. Briggs ADM, Scarborough P, Wolstenholme J. Estimating comparable 
English healthcare costs for multiple diseases and unrelated future 
costs for use in health and public health economic modelling. PLoS One. 
2018;13:e0197257. doi: 10.1371/journal.pone.0197257
 26. Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ. A generic model 
for the assessment of disease epidemiology: the computational basis of 
DisMod II. Popul Health Metr. 2003;1:4. doi: 10.1186/1478-7954-1-4
 27. Cobiac LJ, Scarborough P, Kaur A, Rayner M. The eatwell guide: model-
ling the health implications of incorporating new sugar and fibre guidelines. 
PLoS One. 2016;11:e0167859. doi: 10.1371/journal.pone.0167859
 28. NHS England. 2013/14 CCG Programme Budgetting Benchmarking Tool. 
https://www.england.nhs.uk/prog-budgeting/. Published 2015. Accessed 
June 3, 2019
 29. NHS England. Technical Guide to Allocation Formulae and Pace of Change 
for 2016-17 to 2020-21 Revenue Allocations to Clinical Commission-




 30. Office for National Statistics. Population Estimates for UK, England and 
Wales, Scotland and Northern Ireland. https://www.ons.gov.uk/people-
populationandcommunity/populationandmigration/populationestimates/
datasets/populationestimatesforukenglandandwalesscotlandandnortherni-
reland/mid2014. Published 2018. Accessed June 3, 2019
 31. Office for National Statistics. Deaths. https://www.ons.gov.uk/peoplepopu-
lationandcommunity/birthsdeathsandmarriages/deaths. Published 2019. 
Accessed June 3, 2019
 32. He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction 
on blood pressure: cochrane systematic review and meta-analysis of ran-
domised trials. BMJ. 2013;346:f1325. doi: 10.1136/bmj.f1325
 33. Huang L, Trieu K, Yoshimura S, Neal B, Woodward M, Campbell NRC, Li Q, 
Lackland DT, Leung AA, Anderson CAM, et al. Effect of dose and dura-
tion of reduction in dietary sodium on blood pressure levels: systematic 
review and meta-analysis of randomised trials. BMJ. 2020;368:m315. doi: 
10.1136/bmj.m315
 34. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, MacMahon S, Peto R, 
Aromaa A, Baigent C, Carstensen J, et al. Prospective studies collaboration. 
Age-specific relevance of usual blood pressure to vascular mortality: a meta-
analysis of individual data for one million adults in 61 prospective studies. 
Lancet. 2003;360:1903–1917. doi:10.1016/s0140-6736(02)11911-8.
 35. Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D 
scores for the United Kingdom. Med Decis Making. 2011;31:800–804. doi: 
10.1177/0272989X11401031
 36. Public Health England. Mortality Profile. https://fingertips.phe.org.uk/pro-
file/mortality-profile. Accessed June 15, 2019
 37. HM Treasury. The Green Book. Central Government Guidance on Appraisal 




 38. Public Health England. National Diet and Nutrition Survey: Assessment 
of Dietary Sodium. Adults (19 to 64 Years) in England, 2014. London, 
UK; 2016. https://www.gov.uk/government/statistics/national-diet-and-
nutrition-survey-assessment-of-dietary-sodium-in-adults-in-england- 
2014. Accessed March 20, 2020
 39. World Health Organisation. Regional office for Europe. The Case for Invest-
ing in Public Health.; 2014. http://www.euro.who.int/__data/assets/pdf_
file/0009/278073/Case-Investing-Public-Health.pdf.
 40. Barton P, Andronis L, Briggs A, McPherson K, Capewell S. Effectiveness 
and cost effectiveness of cardiovascular disease prevention in whole popu-
lations: modelling study. BMJ. 2011;343:d4044. doi: 10.1136/bmj.d4044
 41. Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. Popula-
tion strategies to decrease sodium intake and the burden of cardiovascular 
disease: a cost-effectiveness analysis. Ann Intern Med. 2010;152:481–7, 
W170. doi: 10.7326/0003-4819-152-8-201004200-00212
 42. Dodhia H, Phillips K, Zannou MI, Airoldi M, Bevan G. Modelling the impact 
on avoidable cardiovascular disease burden and costs of interventions to 
lower SBP in the England population. J Hypertens. 2012;30:217–226. doi: 
10.1097/HJH.0b013e32834d86ee
 43. Webb M, Fahimi S, Singh GM, Khatibzadeh S, Micha R, Powles J, 
Mozaffarian D. Cost effectiveness of a government supported policy strat-
egy to decrease sodium intake: global analysis across 183 nations. BMJ. 
2017;356:i6699. doi: 10.1136/bmj.i6699
 44. Wilson N, Nghiem N, Eyles H, Mhurchu CN, Shields E, Cobiac LJ, Cleghorn 
CL, Blakely T. Modeling health gains and cost savings for ten dietary salt 
reduction targets. Nutr J. 2016;15:44. doi: 10.1186/s12937-016-0161-1
 45. Schorling E, Niebuhr D, Kroke A. Cost-effectiveness of salt reduction to 
prevent hypertension and CVD: a systematic review. Public Health Nutr. 
2017;20:1993–2003. doi: 10.1017/S1368980017000593
 46. Selmer RM, Kristiansen IS, Haglerod A, Graff-Iversen S, Larsen HK, 
Meyer HE, Bonaa KH, Thelle DS. Cost and health consequences of reducing 
the population intake of salt. J Epidemiol Community Health. 2000;54:697–
702. doi: 10.1136/jech.54.9.697
 47. Palar K, Sturm R. Potential societal savings from reduced sodium consump-
tion in the U.S. adult population. Am J Health Promot. 2009;24:49–57. doi: 
10.4278/ajhp.080826-QUAN-164
 48. Nghiem N, Blakely T, Cobiac LJ, Cleghorn CL, Wilson N. The health 
gains and cost savings of dietary salt reduction interventions, with equity 
and age distributional aspects. BMC Public Health. 2016;16:423. doi: 
10.1186/s12889-016-3102-1
 49. Martikainen JA, Soini EJ, Laaksonen DE, Niskanen L. Health economic 
consequences of reducing salt intake and replacing saturated fat with 
polyunsaturated fat in the adult Finnish population: estimates based on the 
FINRISK and FINDIET studies. Eur J Clin Nutr. 2011;65:1148–1155. doi: 
10.1038/ejcn.2011.78
 50. Cobiac LJ, Vos T, Veerman JL. Cost-effectiveness of interventions to 
reduce dietary salt intake. Heart. 2010;96:1920–1925. doi: 10.1136/hrt. 
2010.199240
 51. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic dis-
ease prevention: health effects and financial costs of strategies to reduce 
salt intake and control tobacco use. Lancet. 2007;370:2044–2053. doi: 
10.1016/S0140-6736(07)61698-5
 52. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, 
Pletcher MJ, Goldman L. Projected effect of dietary salt reductions on 
future cardiovascular disease. N Engl J Med. 2010;362:590–599. doi: 
10.1056/NEJMoa0907355
 53. Mason H, Shoaibi A, Ghandour R, O’Flaherty M, Capewell S, Khatib R, Jabr S, 
Unal B, Sözmen K, Arfa C, et al; MedCHAMPS project team. A cost effec-
tiveness analysis of salt reduction policies to reduce coronary heart disease 
in four Eastern Mediterranean countries. PLoS One. 2014;9:e84445. doi: 
10.1371/journal.pone.0084445
 54. Leyvraz M, Chatelan A, da Costa BR, Taffé P, Paradis G, Bovet P, 
Bochud M, Chiolero A. Sodium intake and blood pressure in children and 
adolescents: a systematic review and meta-analysis of experimental and 
observational studies. Int J Epidemiol. 2018;47:1796–1810. doi: 10.1093/i 
je/dyy121
